

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

17 Jun 2026

### Comparison of intravenous syntocinon in the third stage of labor with rectal misoprostol abortions after the second trimester of pregnancy

#### Protocol summary

##### Summary

In this randomized clinical trial, pregnant women at the gestational age of 14-28 weeks, referred with a letter from the Legal Medicine Organization for termination, or with other conditions such as intra-uterine fetal death and confirmed premature rupture of membranes, are selected. After giving a complete description of the abortion methods/medicines and their possible complications, as well as the research methodology, the eager patients are included in the study. The subjects are then randomly divided into two groups, and all of them receive the same protocol including 200 µg vaginal misoprostol every six hours. In case of a cesarean section history, a reduced dosage of misoprostol is prescribed for 48 hours, and if there is no response to this dosage, other methods such as intra-uterine catheter or high dose of syntocinon, depending on cervix condition and its dilatation, are used. After the removal of fetus and recording the operation time, an intravenous syntocinon including 40 units syntocinon in one liter normal saline is infused to the patients in Group 1 in an hour. The other group receives 400ug rectal misoprostol. Then, a period of one hour is given for the delivery of placenta and the exact time of delivery is recorded. The patient is monitored every quarter in this one hour period, and her vital signs including blood pressure, heart rate, and bleeding rate, measured based on the consumed pads, are recorded. If the placenta is not delivered in an hour and/or in case of the mother's unstable vital signs and/or severe vaginal bleeding, the patient is subjected to the curettage and the uterine contents are extracted and sent for pathological examination. If the placenta is delivered in an hour, the patient is undergone ultrasound to detect the pregnancy remnants. In case of a positive ultrasound result, the patient is subjected to curettage and the extracted uterine contents are sent for pathological examination to reach a definitive diagnosis. The time of the fetus delivery and the time interval between fetus and

placenta removal, as well as the mother's bleeding level, measured based on the decline in hemoglobin rate are recorded (before the abortion and 24 after the abortion).

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015020715795N2**

Registration date: **2015-03-15, 1393/12/24**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2015-03-15, 1393/12/24

##### Registrant information

##### Name

babak sabzivand

##### Name of organization / entity

ardabil medical university

##### Country

Iran (Islamic Republic of)

##### Phone

+98 88 13472

##### Email address

b.sabzivand@arums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Ardabil University of Medical Sciences

##### Expected recruitment start date

2014-08-23, 1393/06/01

##### Expected recruitment end date

2015-03-20, 1393/12/29

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of intravenous syntocinon in the third stage of labor with rectal misoprostol abortions after the second trimester of pregnancy

**Public title**

Comparison of intravenous syntocinon in the third stage of labor with rectal misoprostol abortions after the second trimester of pregnancy

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

Inclusion criteria were: legal permission to go to the end of pregnancy; intrauterine fetal death; gestational age 14 to 18 weeks; premature rupture approved exclusion criteria of the study: allergy or intolerance known as misoprostol; high blood pressure 160/90; severe cardiovascular disease; the patient's general condition is very bad; history of previous uterine scar (except single layer lower uterine segment caesarean section with a transverse incision); severe anemia; coagulation; anticoagulation; active liver disease; uncontrolled seizure disorders; Addison's disease; steroid use

**Age**

No age limit

**Gender**

Female

**Phase**

2-3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **100**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ardabil University of Medical Sciences

**Street address**

Ardabil University of Medical Sciences, Ardabil

**City**

Ardabil

**Postal code****Approval date**

2014-07-27, 1393/05/05

**Ethics committee reference number**

arums.rec.93.47

**Health conditions studied****1****Description of health condition studied**

Intravenous syntocinon in the third stage of labor associated with rectal misoprostol abortions after the second trimester of pregnancy

**ICD-10 code**

Y55

**ICD-10 code description**

Oxytocic drugs

**Primary outcomes****1****Description**

The time of placental removal

**Timepoint**

After fetus delivery

**Method of measurement**

Time

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Two hundred micrograms of misoprostol administered vaginally every 6 hours with 40 units of syntocinon intravenously

**Category**

Treatment - Drugs

**2****Description**

Two hundred micrograms of misoprostol administered vaginally every 6 hours with 400 mcg of misoprostol rectal

**Category**

Treatment - Drugs

**Recruitment centers**

1

**Recruitment center**

**Name of recruitment center**

Ardabil's Alavi Hospital

**Full name of responsible person**

**Street address**

**City**

Ardabil

**Sponsors / Funding sources**

1

**Sponsor**

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Dr. Akbar Pirzadeh

**Street address**

School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

**City**

Ardabil

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Ardabil University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Dr. Nooshin Mobaraki

**Position**

Assistant Professor of Obstetrics and gynecology

**Other areas of specialty/work**

**Street address**

Alavi's hospital, Ardabil University of Medical Sciences

**City**

Ardabil

**Postal code**

**Phone**

+98 45 3323 5033

**Fax**

**Email**

n.mobaraki@arums.ac.ir

**Web page address**

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Dr.Nooshin Mobaraki

**Position**

Assistant Professor of Obstetrics and gynecology

**Other areas of specialty/work**

**Street address**

Alavi's hospital, Ardabil University of Medical sciences

**City**

Ardabil

**Postal code**

**Phone**

+98 45 3323 5033

**Fax**

**Email**

n.mobaraki@arums.ac.ir

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Dr.Nooshin Mobaraki

**Position**

Assistant Professor of Obstetrics and gynecology

**Other areas of specialty/work**

**Street address**

Alavi's hospital, Ardabil University of Medical Sciences

**City**

Ardabil

**Postal code**

**Phone**

+98 45 3323 5033

**Fax**

**Email**

n.mobaraki@arums.ac.ir

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

